DDInter1480 DDInter1016
Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pit
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Pitolisant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Pitolisant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Pitolisant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Pitolisant {u} may lead to a major life threatening interaction when taken with {v} Pasireotide
Pitolisant {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Pitolisant may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Pitolisant may lead to a major life threatening interaction when taken with Pasireotide
Pitolisant may lead to a major life threatening interaction when taken with Ribociclib